The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Immune Checkpoint Inhibitors Market, 2014 - 2024

  • Lowest Price Guaranteed From USD 1,899

  • Published
    November 2014

  • Pages
    192

  • View Count
    5098

Example Insights

An updated edition is available at the following link 

View 2nd edition

  1. The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules.
  2. BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well.
  3. Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market.
  4. Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules.
  5. We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 – 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%.

Overview

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body’s own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). There has been a surge of interest in other classes of immunotherapeutics to manage and treat cancer, including Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies.

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period.

Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

 

Scope of the Report

The “Immune Checkpoint Inhibitors Market, 2014-2024” report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market.

In addition, there are several novel checkpoint inhibitors (e.g. IDO-1, IDO-2, KIR, OX40, CD70 and LAG-3) which have recently gained ground and are expected to retain attention in the future.

One of the key objectives of the study is to review the opportunities laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With three marketed drugs (Yervoy, Keytruda and Opdivo), the market is treading its way towards fulfilling the huge untapped promise. Amongst others, the report elaborates upon the following key areas:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted.
  • Recent partnerships which have taken place over the last five years covering product co-development, licensing and clinical trial collaborations
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The base year for the report is 2013. The report provides short-mid term and long term market forecasts for the period 2014 - 2019 and 2019 - 2024, respectively. The research, analysis and insights presented in this report include potential sales of several Immune Checkpoint Inhibitors; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analyzed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  presents an executive summary of the report. It offers a high level view on where the Immune Checkpoint Inhibitors market is headed in the mid-long term.

Chapter 3  provides a general introduction to Immune Checkpoint Inhibitors. In this section we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and, specifically, the emergence of Immune Checkpoint Inhibitors.

Chapter 4  provides a comprehensive landscape of the Immune Checkpoint Inhibitors market. This chapter includes information on ~60 inhibitors which are currently in different stages of development (both clinical and pre-clinical / discovery). The detailed analysis of this development pipeline includes information on types of molecules, most commonly targeted indications, current phases of development and the likely launch timelines.

Chapter 5  focuses on CTLA-4 inhibitors and presents the current scenario and the future outlook for this specific class of molecules. The chapter includes detailed drug profiles of the marketed and drugs under development. We have presented information on several parameters such as history of development, clinical trial results, manufacturing, cost and reimbursement. It includes the likely sales forecast of the drugs currently in phase III or higher stage of development.

Chapter 6  focuses on PD-1 and PD-L1 inhibitors and presents the current scenario and the future outlook for this specific class of inhibitors. As with the CTLA-4 inhibitors, this chapter provides a holistic view on the various drugs belonging to this class and their future sales potential.

Chapter 7  focuses on novel inhibitors such as IDO-1, IDO-2, KIR, OX40, CD70, LAG-3 and more. As in the earlier two chapters, we have provided detailed drug profiles and the future outlook for these new set of inhibitors.

Chapter 8  includes an elaborate discussion on the various collaborations and partnerships which have been forged amongst the players in the market over the last several years.

Chapter 9  offers a comprehensive competitive landscape of various therapies being used for the treatment of certain oncological indications; these indications have been the prime focus of companies developing Immune Checkpoint Inhibitors. 

Chapter 10  provides the detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline drugs and recent collaborations and developments.

Chapter 11  summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Cancer Therapeutics and Immuno-Oncology
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining A Strong Foothold
3.3.1. Activation and Suppression Immunotherapies
3.4. Immuno-Oncology (Cancer Immunotherapy)
 
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Product Class
3.5.2.1. Monoclonal Antibodies (mAbs)
3.5.2.2. Cytokines
3.5.2.3. Cell Based Therapies
3.5.2.4. Immune Checkpoint Inhibitors
 
4. Current Market Landscape
4.1. Scope and Observations
4.1.1. Common Targets for Immune Checkpoint Inhibitors
4.2. Three Approved Immune Checkpoint Inhibitors in Market
4.3. Immune Checkpoint Inhibitors: Clinical and Preclinical Pipeline
4.3.1. Bristol Myers Squibb Leads Immune Checkpoint Inhibitors Market
4.3.2. Companies Evaluating Diverse Checkpoint Targets
4.4. Four Drugs in Late Stage Development
4.5. Companies Evaluating Different Molecule Types: From Monoclonal Antibodies to Fusion Proteins
4.6. Overall Future Outlook: Sales Forecast, 2014 - 2024
4.6.1. Scope and Forecast Methodology
4.6.2. Overall Market Size and Forecast
 
5. CTLA-4 Inhibitors: Key Molecules and Future Outlook
5.1. Mechanism of Action
5.2. Pioneers of Immune Checkpoint Inhibitors Market
5.3. Pipeline Analysis
5.3.1. Limited Molecules in Pipeline
5.3.2. KAHR Medical Developing A Fusion Protein
 
5.4. Yervoy (Bristol Myers Squibb)
5.4.1. Introduction
5.4.2. History of Development
5.4.3. Dosage and Manufacturing
5.4.4. Treatment Cost and Reimbursement
5.4.5. Current Status of Development
5.4.6. Key Clinical Trial Results
5.4.7. Historical Sales, 2011 -H1 2014
5.4.8. Patent Expiry
5.4.9. Collaborations
5.4.10. Yervoy Sales Forecast, 2014 - 2024
 
5.5. Tremelimumab (MedImmune)
5.5.1. Introduction
5.5.2. History of Development
5.5.3. Current Status of Development
5.5.4. Key Clinical Trial Results
5.5.5. Target Population
5.5.6. Future Plans
5.5.7. Tremelimumab Sales Forecast, 2014 - 2024
 
5.6. CTLA-4 Inhibitors: Roots Analysis’ Perspective
 
6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook
6.1. Mechanism of Action
6.2. Two Recent Launches Have Strengthened the Market Sentiments
6.2.1. PD-1 / PD-L1 Inhibitors Pipeline Analysis
6.2.2. Market Attracting Both Large and Small Pharma Companies
6.2.3. Two Faces of a Coin
6.2.4. Majority Candidates in Early Stages of Development
6.2.5. Drug Developers Moving Beyond Monoclonal Antibodies
 
6.3. Opdivo (Bristol Myers Squibb)
6.3.1. Introduction
6.3.2. History of Development
6.3.3. Dosage and Manufacturing
6.3.4. Treatment Cost and Reimbursement
6.3.5. Patent Expiry
6.3.6. Current Status of Development
6.3.7. Key Clinical Trial Results
6.3.8. Collaborations
6.3.9. Opdivo Sales Forecast, 2014 - 2024
 
6.4. Keytruda (Merck)
6.4.1. Introduction
6.4.2. Dosage and Manufacturing
6.4.3. Patent Expiry
6.4.4. Treatment Cost and Reimbursement
6.4.5. Current Status of Development
6.4.6. Key Clinical Trial Results
6.4.7. Collaborations
6.4.8. Keytruda Sales Forecast, 2014 – 2024
 
6.5. MPDL3280A (Roche)
6.5.1. Introduction
6.5.2. Current Status of Development
6.5.3. Key Clinical Trial Results
6.5.4. Collaborations
6.5.5. MPDL3280A Sales Forecast, 2014 - 2024
 
6.6. MEDI4736 (MedImmune)
6.6.1. Introduction
6.6.2. Current Status of Development
6.6.3. Development of a Companion Diagnostic
6.6.4. Key Clinical Trial Results
6.6.5. Collaborations
6.6.6. MEDI4736 Sales Forecast, 2014 - 2024
 
6.7. PD -1 And PD- L1 Inhibitors: Roots Analysis’ Perspectives
 
7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook
7.1. Rush for the Novel Immune Checkpoints
7.2. IDO Inhibitors: The Most Sought After Drug Class Under Development
7.3. Small Pharma Dominates the Novel Checkpoint Space
7.4. Elotuzumab is the Only Drug in Late Stage Development
 
7.5. Elotuzumab (Bristol Myers Squibb)
7.5.1. Introduction
7.5.2. History of Development
7.5.3. Mechanism of Action
7.5.4. Patent Information
7.5.5. Current Status of Development
7.5.6. Key Clinical Trial Results
7.5.7. Collaborations
7.5.8. Future Plans
7.5.9. Elotuzumab Sales Forecast, 2014 – 2024
 
7.6. INCB024360 (Incyte Corporation)
7.6.1. Introduction
7.6.2. Patent Information
7.6.3. Manufacturing
7.6.4. Current Status of Development
7.6.5. Key Clinical Trial Results
7.6.6. Collaborations
 
7.7. Indoximod (NewLink Genetics)
7.7.1. Introduction
7.7.2. Manufacturing
7.7.3. Current Status of Development
7.7.4. Key Clinical Trial Results
7.7.5. Patent Information
7.7.6. Collaborations
7.7.7. Future Plans
 
7.8. Lirilumab (Bristol Myers Squibb)
7.8.1. Introduction
7.8.2. Mechanism of Action
7.8.3. Current Status of Development
7.8.4. Key Clinical Trial Results
7.8.5. Collaborations
7.8.6. Future Plans
 
7.9. Novel Checkpoint Inhibitors: Roots Analysis’ Perspectives
 
8. Competition in Key Indication Areas
8.1. Chapter Overview
8.2. Competition in Melanoma Market
8.3. Competition in Malignant Mesothelioma Market
8.4. Competition in NSCLC Market
8.5. Competition in Multiple Myeloma Market
8.6. Competition in the Ovarian Cancer Market
8.7. Competition in Bladder Cancer Market
 
9. Deals and Partnerships
9.1. Chapter Overview
9.2. Clinical Trial Collaborations Are Commonplace
9.3. 2014 Has Been Very Active in Terms of Number of Collaborations
9.4. Large Pharmaceutical Companies Acquiring to Expand Pipelines
9.5. Co-development and Commercialization Agreements
9.6. Product Licensing Agreements
9.7. Clinical Trial Collaborations to Validate Combination Therapies
9.8. Contract Manufacturing Agreement
9.9. Research Collaborations
 
10. Company Profiles
10.1. Chapter Overview
10.2. Bristol Myer Squibb
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.2.4. Collaborations
 
10.3. AstraZeneca
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.3.4. Collaborations
 
10.4. Merck & Co.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.4.4. Collaborations
 
10.5. Roche / Genentech
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.5.4. Collaborations
 
10.6. Incyte Corporation
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.6.4. Collaborations
 
10.7. NewLink Genetics
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.7.4. Collaborations
 
10.8. Other Companies
10.8.1. arGEN-X
10.8.1.1. Technology Platforms
10.8.1.2. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.1.3. Collaborations
 
10.8.2. Seattle Genetics
10.8.2.1. Financial Performance
10.8.2.2. Technology Platforms
10.8.2.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.2.4. Collaborations
 
10.8.3. Pfizer
10.8.3.1. Financial Performance
10.8.3.2. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.3.3. Collaborations
 
10.8.4. MacroGenics
10.8.4.1. Financial Performance
10.8.4.2. Technology Platforms
10.8.4.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.4.4. Collaborations
 
10.8.5. Celldex Therapeutics
10.8.5.1. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.5.2. Collaborations
 
10.8.6. CureTech
10.8.6.1. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.6.2. Collaborations
 
10.8.7. Immutep
10.8.7.1. Technology Platforms
10.8.7.2. Immutep Immune Checkpoint Inhibitors Pipeline, 2014
10.8.7.3. Collaborations
 
10.8.8. Innate Pharma
10.8.8.1. Financial Performance
10.8.8.2. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.8.3. Collaborations
 
10.8.9. Sorrento Therapeutics
10.8.9.1. Financial Performance
10.8.9.2. Technology Platforms
10.8.9.3. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.9.4. Collaborations
 
10.8.10. GlaxoSmithKline
10.8.10.1. Financial Performance
10.8.10.2. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.10.3. Collaborations
 
10.8.11. GITR, Inc.
10.8.11.1. Immune Checkpoint Inhibitors Pipeline, 2014
10.8.11.2. Collaborations
 
11. Conclusion
11.1. Immune Checkpoint Inhibitors: A New Hope For Cancer Patients
11.2. Current Flag Bearers: PD-1 and PD-L1
11.3. Active Collaborations Likely To Be The Key To Future Success
11.4. With Several Blockbusters In The Pipeline, The Overall Opportunity Is Huge
11.5. Concluding Remarks
 
12. Appendix 1: Tabulated Data
 
13. Appendix 2: List of Companies and Organizations

List of Figures

Figure 3.1  The Four Pillars of Cancer Therapy
Figure 3.2  Passive and Active Cancer Immunotherapies
Figure 4.1  Immune Checkpoint Inhibitors: Distribution by Drug Developers
Figure 4.2  Immune Checkpoint Inhibitors: Distribution by Targets
Figure 4.3  Immune Checkpoint Inhibitors: Distribution by Phase of Development
Figure 4.4  Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Figure 4.5  Immune Checkpoint Inhibitors: Overall Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 5.1  CTLA-4 Pipeline: Distribution by Highest Phase of Development
Figure 5.2  CTLA-4 Pipeline: Distribution by Type of Molecule
Figure 5.3  Yervoy Sales (USD Million), 2011 - H1 2014
Figure 5.4  Yervoy Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 5.5  Tremelimumab Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 5.6  CTLA-4 Inhibitors: Drivers and Restraints
Figure 6.1  PD-1 / PD-L1 Pipeline: Distribution by Drug Developer
Figure 6.2  PD-1 / PD-L1 Pipeline: Distribution by Target
Figure 6.3  PD-1 / PD-L1 Pipeline: Distribution by Phase of Development
Figure 6.4  PD-1 / PD-L1 Pipeline: Distribution by Type of Molecule
Figure 6.5  Opdivo Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 6.6  Keytruda Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 6.7  RG7446 Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 6.8  MEDI4736 Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 6.9  PD-1 and PD-L1 Inhibitor: Drivers and Restraints
Figure 7.1  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Target
Figure 7.2  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Companies
Figure 7.3  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Phase of Development
Figure 7.4  Elotuzumab Sales Forecast, 2014 - 2024: Base Scenario (USD Million)
Figure 7.5  Novel Immune Checkpoint Inhibitors: Drivers and Restraints
Figure 9.1  Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Type
Figure 9.2  Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Year of Partnership
Figure 9.3  Clinical Trial Collaborations: Distribution by Target
Figure 10.1  BMS Revenues (USD Billion), 2011 - H1 2014
Figure 10.2  BMS Revenues (USD Million): Distribution by Therapeutic Areas, H1 2013 - H1 2014
Figure 10.3  AstraZeneca Revenues (USD Billion), 2011 - H1 2014
Figure 10.4 Merck Revenues (USD Billion), 2011 - 2013
Figure 10.5 Roche Revenues (CHF Billion), 2011 - H1 2014: Distribution by Business Segments
Figure 10.6  Roche Pharmaceutical Sales, (CHF Billion), H1 2014: Distribution by Therapeutic Areas
Figure 10.7  Incyte Corporation Revenues (USD Million), 2011 - H1 2014
Figure 10.8  NewLink Genetics Revenues (USD ‘000), 2011 - H1 2014
Figure 10.9  Seattle Genetics Revenues (USD Million), 2011 - H1 2014
Figure 10.10  Pfizer Revenues (USD Billion), 2011 - H1 2014
Figure 10.11  MacroGenics Revenues (USD Million), 2011 - H1 2014
Figure 10.12  Innate Pharma Revenues (EUR Million), 2011 - H1 2014
Figure 10.13  Sorrento Therapeutics Revenues (USD Million), 2011 - H1 2014
Figure 10.14  GlaxoSmithKline Revenues (GBP Billion), 2011 - H1 2014
Figure 11.1 Immune Checkpoint Inhibitors Market (USD Billion), 2017, 2021 and 2024

List of Tables

Table 3.1  FDA Approved Antibody Based Therapeutics for Cancer
Table 4.2  Immune Checkpoint Inhibitors: Marketed and Clinical Pipeline, 2014
Table 4.4  Immune Checkpoint Inhibitors: Current Development Phase and Expected Launch Year of Drugs
Table 5.2  Yervoy: History of Development
Table 5.3  Yervoy: Dosage and Packaging
Table 5.4  Yervoy: Current Status of Development (Single Agent and Combination Therapy)
Table 5.5  Tremelimumab: Current Status of Development (Single Agent and Combination Therapy)
Table 6.2  PD-1 / PD-L1 Landscape Analysis
Table 6.3  Opdivo: Current Status of Development (Single Agent and Combination Therapy)
Table 6.4  Keytruda: Current Status of Development (Single Agent and Combination Therapy)
Table 6.5  MPDL3280A: Current Status of Development (Single Agent and Combination Therapy)
Table 6.6  MEDI4736: Current Status of Development (Single Agent and Combination Therapy)
Table 7.2  Elotuzumab: Current Status of Development (Single Agent and Combination Therapy)
Table 7.3  INCB024360: Current Status of Development (Single Agent and Combination Therapy)
Table 7.4  Indoximod: Current Status of Development (Single Agent and Combination Therapy)
Table 7.5  NewLink Genetics: Patent Portfolio Related to IDO Inhibitors
Table 7.6  Lirilumab: Current Status of Development (Single Agent and Combination Therapy)
Table 8.1  Comparison of Marketed Targeted Therapeutics for Melanoma
Table 8.2  Comparison of Marketed Targeted Therapeutics for Metastatic NSCLC
Table 9.1  Immune Checkpoint Inhibitors Market: Acquisitions
Table 9.2  Immune Checkpoint Inhibitors Market: Co-Development and Commercialization Agreements
Table 9.3  Immune Checkpoint Inhibitors Market: Product Licensing Agreements
Table 9.4  Immune Checkpoint Inhibitors Market: Clinical Trial Collaborations
Table 9.5  Immune Checkpoint Inhibitors Market: Contract Manufacturing Agreements
Table 9.6  Immune Checkpoint Inhibitors Market: Research Collaborations
Table 10.1  BMS: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.2  BMS: Immune Checkpoint Inhibitors Partnerships
Table 10.3  AstraZeneca / MedImmune: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.4  AstraZeneca / MedImmune: Immune Checkpoint Inhibitors Partnerships
Table 10.5  Merck: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.6  Merck: Immune Checkpoint Inhibitors Partnerships
Table 10.7  Roche / Genentech: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.8  Roche / Genentech: Immune Checkpoint Inhibitors Partnerships
Table 10.9  Incyte Corporation: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.10  Incyte Corporation: Immune Checkpoint Inhibitors Partnerships
Table 10.11  NewLink Genetics: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.12  arGEN-X: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.13  Seattle Genetics: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.14  Pfizer: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.15  Pfizer: Immune Checkpoint Inhibitors Partnerships
Table 10.16  MacroGenics: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.17  Celldex Therapeutics: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.18  CureTech: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.19  Immutep: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.20  Innate Pharma: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.21  Sorrento Therapeutics: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.22  GSK: Immune Checkpoint Inhibitors Pipeline, 2014
Table 10.23  GITR: Immune Checkpoint Inhibitors Pipeline, 2014
Table 12.1  Immune Checkpoint Inhibitors: Distribution by Targets
Table 12.2  Immune Checkpoint Inhibitors: Detailed Pipeline (Single Agent and Combination Therapy)
Table 12.3  Immune Checkpoint Inhibitors: Distribution by Phase of Development
Table 12.4  Immune Checkpoint Inhibitors: Distribution by Type of Molecules
Table 12.5  Immune Checkpoint Inhibitors: Overall Sales Forecast, 2014-2024: Base Scenario (USD Million)
Table 12.6  Immune Checkpoint Inhibitors: Overall Sales Forecast, 2014-2024: Conservative Scenario (USD Million)
Table 12.7  Immune Checkpoint Inhibitors:  Overall Sales Forecast, 2014-2024: Optimistic Scenario (USD Million)
Table 12.8  CTLA-4 Pipeline: Distribution by Phase of Development
Table 12.9  CTLA-4 Pipeline: Distribution by Type of Molecule
Table 12.10  Yervoy Sales (USD Million), 2011- H1 2014
Table 12.11  Yervoy Sales Forecast, 2014-2024: Base Scenario (USD Million)
Table 12.12  Yervoy Sales Forecast, 2014-2024: Conservative Scenario (USD Million)
Table 12.13  Yervoy Sales Forecast, 2014-2024: Optimistic Scenario (USD Million)
Table 12.14  Tremelimumab Sales Forecast, 2014-2024: Base Scenario (USD Million)
Table 12.15  Tremelimumab Sales Forecast, 2014-2024: Conservative Scenario (USD Million)
Table 12.16  Tremelimumab Sales Forecast, 2014-2024: Optimistic Scenario (USD Million)
Table 12.17  PD-1/ PD-L1 Pipeline: Distribution by Drug Developer
Table 12.18  PD-1/ PD-L1 Pipeline: Distribution by Target
Table 12.19  PD-1/ PD-L1 Pipeline: Distribution by Phase of Development
Table 12.20  PD-1/ PD-L1 Pipeline: Distribution by Type of Molecule
Table 12.21  Opdivo Sales Forecast, 2014-2024: Base Scenario (USD Million)
Table 12.22  Opdivo Sales Forecast, 2014-2024: Conservative Scenario (USD Million)
Table 12.23  Opdivo Sales Forecast, 2014-2024: Optimistic Scenario (USD Million)
Table 12.24  Keytruda Sales Forecast, 2014-2024: Base Scenario (USD Million)
Table 12.25  Keytruda Sales Forecast, 2014-2024: Conservative Scenario (USD Million)
Table 12.26  Keytruda Sales Forecast, 2014-2024: Optimistic Scenario (USD Million)
Table 12.27  RG7446 Sales Forecast, 2014-2024: Base Scenario (USD Million)
Table 12.28  RG7446 Sales Forecast, 2014-2024: Conservative Scenario (USD Million)
Table 12.29  RG7446 Sales Forecast, 2014-2024: Optimistic Scenario (USD Million)
Table 12.30  MEDI4736 Sales Forecast, 2014-2024: Base Scenario (USD Million)
Table 12.31  MEDI4736 Sales Forecast, 2014-2024: Conservative Scenario (USD Million)
Table 12.32  MEDI4736 Sales Forecast, 2014-2024: Optimistic Scenario (USD Million)
Table 12.33  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Target
Table 12.34  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Companies
Table 12.35  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Phase of Development
Table 12.36  Elotuzumab Sales Forecast, 2014-2024: Base Scenario (USD Million)
Table 12.37  Elotuzumab Sales Forecast, 2014-2024: Conservative Scenario (USD Million)
Table 12.38  Elotuzumab Sales Forecast, 2014-2024: Optimistic Scenario (USD Million)
Table 12.39  Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Type
Table 12.40  Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Year
Table 12.41  Clinical Trial Collaborations: Distribution by Target
Table 12.42  BMS Revenues (USD Billion), 2011- H1 2014
Table 12.43  BMS Revenues (USD Million): Distribution by Therapeutic Areas, H1 2013 - H1 2014
Table 12.44  AstraZeneca Revenues (USD Billion), 2011 - H1 2014
Table 12.45  Merck Revenues (USD Billion), 2011 - 2013
Table 12.46  Roche Revenues (CHF Billion), 2011 - H1 2014: Distribution by Business Segments
Table 12.47  Incyte Corporation Revenues (USD Million), 2011 - H1 2014
Table 12.48  NewLink Genetics Revenues (USD ‘000), 2011 - H1 2014
Table 12.49  Seattle Genetics Revenues (USD Million), 2011 - H1 2014
Table 12.50  Pfizer Revenues (USD Billion), 2011 - H1 2014
Table 12.51  MacroGenics Revenues (USD Billion), 2011 - H1 2014
Table 12.52  Innate Pharma Revenues (USD Million), 2011 - H1 2014
Table 12.53  Sorrento Therapeutics Revenues (USD ‘000), 2011 - H1 2014
Table 12.54  GlaxoSmithKline Revenues (GBP Billion), 2011 - H1 2014

Listed Companies

The following companies and organisations have been mentioned in the report.

  1. Aurigene
  2. 4-Antibody AG
  3. Abbott
  4. AbbVie
  5. Adimab
  6. Advaxis
  7. Agenus
  8. AgonOX
  9. Ambrx
  10. Amgen
  11. Amplimmune
  12. AnaptysBio
  13. arGEN-X
  14. American Society of Clinical Oncology
  15. Azienda Ospedaliera Universitaria Senese
  16. Bayer
  17. BeiGene
  18. Bio-Matrix Scientific Group
  19. BioWa
  20. Boehringer Ingelheim
  21. Bristol Myers Squibb
  22. Celgene
  23. Cell Genesys 
  24. Celldex Therapeutics
  25. Clinical Research Institute 
  26. Compugen
  27. CoStim Pharmaceuticals
  28. CureTech
  29. Eddingpharm
  30. Facet Biotech
  31. Five Prime Therapeutics
  32. Georgia Health Sciences University
  33. Gilead BioSciences
  34. GITR /Tolerx
  35. GlaxoSmithKline
  36. Gustave Roussy Institute 
  37. HealthCare Ventures
  38. IDM
  39. Immutep
  40. Incyte Corporation
  41. Innate Pharma
  42. iTeos Therapeutics
  43. KAHR Medical
  44. Kyowa Hakko Kirin
  45. Lankenau Institute for Medical Research (LIMR)
  46. Laureate Pharma
  47. Lee's Pharma 
  48. Lonza Biologics
  49. Ludwig Cancer Research
  50. MacroGenics 
  51. Masonic Cancer Center
  52. Medarex
  53. MedImmune/AstraZeneca
  54. Medivation
  55. Merck
  56. Merck Serono
  57. Millennium Pharmaceuticals
  58. MolMed S.p.A
  59. MorphoSys
  60. MRC Technology
  61. NewLink Genetics
  62. Novartis
  63. Novo Nordisk
  64. Oncothyreon
  65. Ono Pharmaceutical
  66. Onyx (subsidiary of Amgen) 
  67. Orega Biotech
  68. PDL Biopharma
  69. Pfizer
  70. Pierre Fabre
  71. Prima BioMed 
  72. Recipharm Cobra Biologics
  73. Regis Technologies 
  74. Roche/Genentech
  75. Samsung Biologics
  76. Seattle Genetics
  77. Servier
  78. Sorrento Therapeutics
  79. Spring Bioscience
  80. Tesaro
  81. ToleroTech
  82. University of California, Berkeley
  83. University of Iowa Pharmaceutical Services
  84. University of Minnesota 
  85. University of Texas 
  86. Ventana Medical Systems

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com